TY - JOUR
T1 - Type 2 Diabetes Pharmacoepidemiology Update 2014
T2 - Safety Versus Efficacy
AU - Singh, Sonal
N1 - Publisher Copyright:
© 2014, Springer Science+Business Media New York.
PY - 2014/10/26
Y1 - 2014/10/26
N2 - The number of available options for type 2 diabetes has increased steadily over the last decade. These include the insulins, metformin, sulfonylureas, thiazolidinediones, incretin-based therapies, and sodium-glucose cotransporter 2 inhibitors. In this paper, the safety and efficacy of these agents are reviewed with a view on updated findings that have emerged over the last few years. Most drugs for type 2 diabetes effectively lower glycated hemoglobin. Their efficacy is in the range of approximate 0.8–1.5 % reduction in glycated hemoglobin for most agents. No drug for type 2 diabetes has been shown to reduce cardiovascular risk in a clinical trial which represents a gap in the therapeutic armamentarium for type 2 diabetes. Recent evidence has linked the thiazolidinediones to bladder cancer and raised concerns about pancreatic cancer with incretins, which requires further confirmation. The rapidly emerging evidence in the field of pharmacoepidemiology of diabetes will continue to provide answers to important questions on safety and efficacy in 2015 and beyond.
AB - The number of available options for type 2 diabetes has increased steadily over the last decade. These include the insulins, metformin, sulfonylureas, thiazolidinediones, incretin-based therapies, and sodium-glucose cotransporter 2 inhibitors. In this paper, the safety and efficacy of these agents are reviewed with a view on updated findings that have emerged over the last few years. Most drugs for type 2 diabetes effectively lower glycated hemoglobin. Their efficacy is in the range of approximate 0.8–1.5 % reduction in glycated hemoglobin for most agents. No drug for type 2 diabetes has been shown to reduce cardiovascular risk in a clinical trial which represents a gap in the therapeutic armamentarium for type 2 diabetes. Recent evidence has linked the thiazolidinediones to bladder cancer and raised concerns about pancreatic cancer with incretins, which requires further confirmation. The rapidly emerging evidence in the field of pharmacoepidemiology of diabetes will continue to provide answers to important questions on safety and efficacy in 2015 and beyond.
KW - Antidiabetic drugs
KW - Efficacy
KW - Pharmacoepidemiology
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=84920288871&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920288871&partnerID=8YFLogxK
U2 - 10.1007/s11892-014-0563-4
DO - 10.1007/s11892-014-0563-4
M3 - Review article
C2 - 25363547
AN - SCOPUS:84920288871
SN - 1534-4827
VL - 14
JO - Current diabetes reports
JF - Current diabetes reports
IS - 12
M1 - 563
ER -